APUS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Apimeds Pharmaceuticals US Inc (APUS) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is experiencing significant bearish momentum, lacks positive trading signals, and has weak financial performance. Additionally, there are no strong positive catalysts or influential trading activity to support a buy decision.
The stock is in a bearish trend with the MACD histogram below zero and negatively expanding. The RSI is at 19.881, indicating the stock is oversold. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support levels are at 1.181 and 0.959, with resistance at 1.899 and 2.121. The stock has experienced a significant price drop of -24.14% in the regular market and an additional -4.55% in post-market trading.
The company has scheduled a Type C meeting with the FDA on May 4, 2026, to discuss the development of LT-100, a non-opioid biologic for osteoarthritis treatment. LT-100 has historical approval in South Korea and is being advanced in the U.S. with rigorous development standards.
The stock has experienced a significant price drop (-24.14% in the regular market and -4.55% in post-market). Technical indicators show strong bearish momentum. Financial performance is weak, with no revenue and negative net income. Additionally, there are no significant insider or hedge fund trading trends, and no recent congress trading data is available.
In 2025/Q3, the company reported no revenue growth (0% YoY), a net income of -1,781,255 (up 435.68% YoY), and an EPS of -0.14 (up 366.67% YoY). Gross margin remained at 0%. Despite improvements in net income and EPS, the company is still operating at a loss with no revenue.
No analyst rating or price target data is provided for APUS.
